Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Human immunodeficiency virus (HIV)-infected subjects aged 6 years or older~* Viral load \< 50,000 copies/mL and CD4+ T cell count \>= 200/uL within 6 months before study vaccination~* Receiving stable highly active antiretroviral therapy (HAART) or not currently receiving any antiretroviral therapy~* No previous vaccination with a pneumococcal vaccine~* Subject or parent/legal guardian able to complete an electronic diary~Exclusion Criteria:~* Acquired immune deficiency syndrome (AIDS) at time of enrollment~* Current illicit substance and/or alcohol abuse~* History of active chronic viral hepatitis~* Previous anaphylactic reaction to a vaccine or vaccine-related component~* Serious chronic disorders including metastatic malignancy and end-stage renal disease

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart

Based on this trial design, predict the completion outcome and termination type (if applicable).